19 results
DEF 14A
SLRN
Acelyrin Inc
22 Apr 24
Definitive proxy
4:10pm
. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, from April 2000 to January 2002 … and held various roles at Merck & Co. Inc. from June 1989 to March 2000, including as a senior executive in research and development. Dr. Seidenberg has
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
of preclinical and clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives … was recorded as research and development expense in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021
8-K
EX-99.1
SLRN
Acelyrin Inc
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
a result of expansion of the izokibep program across indications and a one-time $123.1 million in-process research and development (IPR&D) expense, plus … share and per share data)
Year Ended December 31,
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss
8-K
EX-99
gbhj63uw obee7iofum
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
8-K
EX-99.1
bwnhad
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
EX-99.1
3ezvhiop5241h0
15 Jun 23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
4:22pm
10-Q
cd0sc 3m9yg49qt23r
15 Jun 23
Quarterly report
4:19pm
424B4
54mz2i3fxz5y9ve3g4m
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
7l03n
1 May 23
IPO registration (amended)
6:10am
CORRESP
g2k4fwnt vs4
20 Apr 23
Correspondence with SEC
12:00am
S-1
EX-10.13
popm0k
13 Apr 23
IPO registration
5:10pm
S-1
EX-2.1
3z2syupf3
13 Apr 23
IPO registration
5:10pm
S-1
kcnqbwfgb063uaay
13 Apr 23
IPO registration
5:10pm
CORRESP
qy8lpam
13 Apr 23
Correspondence with SEC
12:00am
UPLOAD
3ytw0uji7o vl
6 Apr 23
Letter from SEC
12:00am
- Prev
- 1
- Next